Details of the Drug

General Information of Drug (ID: DM8GJA7)

• Drug Name: N-(arylamino)sulfonamide derivative 1
• Synonyms: PMID28594589-Compound-TABLE3c8
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 560.3
  Logarithm of the Partition Coefficient (xlogp); 2.9
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 10
• Chemical Identifiers:
  Formula: C18H17F4IN2O4S
  IUPAC Name: 1-(2,3-dihydroxypropyl)-N-[3,4,6-trifluoro-2-(2-fluoro-4-iodoanilino)phenyl]cyclopropane-1-sulfonamide
  Canonical SMILES: C1CC1(CC(CO)O)S(=O)(=O)NC2=C(C(=C(C=C2F)F)F)NC3=C(C=C(C=C3)I)F
  InChI: InChI=1S/C18H17F4IN2O4S/c19-11-5-9(23)1-2-14(11)24-17-15(22)12(20)6-13(21)16(17)25-30(28,29)18(3-4-18)7-10(27)8-26/h1-2,5-6,10,24-27H,3-4,7-8H2
  InChIKey: DDZSGPZIFZFUSF-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 15985394
  TTD ID: D0OR2V

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ERK activator kinase (MEK)	TTZCRP3	NOUNIPROTAC	Inhibitor	[1]

References

• [1] MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.